Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CATX

Perspective Therapeutics Inc

Feb 17 • 02:41PM ET

4.85

+0.15 3.18 %

Healthcare • Medical Devices • USA • AMEX

Peers: TGTX KPTI AVXL IMUX XOMA CLPT CYCN ONCT KALA MNOV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.46	Insider Own	27.72%	Shs Outstand	74.34M	Perf Week	0.20%
Market Cap	552.43M	Forward P/E	-	EPS next Y	-1.23	Insider Trans	0.10%	Shs Float	60.39M	Perf Month	95.54%
Enterprise Value	381.60M	PEG	-	EPS next Q	-0.36	Inst Own	94.73%	Short Float	15.80%	Perf Quarter	134.28%
Income	-105.80M	P/S	516.29	EPS this Y	-0.78%	Inst Trans	-4.41%	Short Ratio	2.78	Perf Half Y	34.34%
Sales	1.07M	P/B	1.49	EPS next Y	0.77%	ROA	-30.98%	Short Interest	9.54M	Perf YTD	76.35%
Book/sh	3.26	P/C	3.17	EPS next 5Y	0.24%	ROE	-37.24%	52W High	6.16 -21.27%	Perf Year	60.58%
Cash/sh	1.53	P/FCF	-	EPS past 3/5Y	-55.62% -9.86%	ROIC	-43.22%	52W Low	1.60 203.09%	Perf 3Y	26.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-47.51% -27.61%	Gross Margin	-174.33%	Volatility	9.76% 18.28%	Perf 5Y	-71.47%
Dividend TTM	-	EV/Sales	356.64	EPS Y/Y TTM	-57.13%	Oper. Margin	-8802.51%	ATR (14)	0.54	Perf 10Y	-30.76%
Dividend Ex-Date	-	Quick Ratio	8.66	Sales Y/Y TTM	-	Profit Margin	-9841.86%	RSI (14)	64.10	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	8.66	EPS Q/Q	-63.24%	SMA20	21.25%	Beta	1.72	Target Price	13.14
Payout	-	Debt/Eq	0.01	Sales Q/Q	-43.36%	SMA50	51.82%	Rel Volume	0.25	Prev Close	4.70
Employees	140	LT Debt/Eq	0.01	Earnings	Nov 10 AMC	SMA200	50.29%	Avg Volume	3.43M	Price	4.85
IPO	Nov 10, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.03% -14.48%	Trades		Volume	693,111	Change	3.18%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Resumed	Truist	Buy	$12
Oct-10-25	Initiated	BTIG Research	Buy	$14
Mar-13-25	Initiated	H.C. Wainwright	Buy	$10
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$15
Nov-25-24	Downgrade	BofA Securities	Buy → Neutral	$24 → $5
Oct-24-24	Initiated	UBS	Buy	$20
Oct-01-24	Initiated	Wedbush	Outperform	$25
Sep-25-24	Initiated	Truist	Buy	$21
Jul-25-24	Initiated	BofA Securities	Buy	$24
May-09-24	Initiated	Cantor Fitzgerald	Overweight

Today 11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results (GlobeNewswire)
Feb-02-26 08:35AM	Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +33.51%
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire) -11.03%
Jan-12-26 07:00AM	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -15.14%
07:00AM	Loading…
Jan-09-26 07:00AM	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-18-25 07:00AM	Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 07:00AM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium (GlobeNewswire) +8.14%
Nov-20-25 07:00AM	Perspective Therapeutics to Participate in Upcoming December Conferences (GlobeNewswire) -7.83%
Nov-10-25 04:27PM	Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results (GlobeNewswire)
Nov-06-25 07:45AM	Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Nov-04-25 05:25PM	Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates (Zacks) -10.38%
Oct-31-25 07:00AM	Perspective Therapeutics to Participate in Upcoming November Conferences (GlobeNewswire)
Oct-29-25 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Loading…
Oct-24-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-20-25 04:00AM	Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025 (GlobeNewswire) -28.95%
Oct-02-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors (GlobeNewswire)
Sep-15-25 07:00AM	Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Sep-04-25 07:00AM	Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer (GlobeNewswire)
Sep-03-25 07:00AM	Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors (GlobeNewswire)
Aug-26-25 07:00AM	Perspective Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-13-25 06:50AM	Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results (GlobeNewswire)
Aug-12-25 06:05PM	Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.99%
Aug-06-25 05:35PM	electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 07:15AM	Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates (Zacks)
Jul-24-25 12:45PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025 (GlobeNewswire)
12:45PM	Perspective Therapeutics Announces Acceptance of VMT--NET Data for Presentation at the ESMO Congress 2025 (GlobeNewswire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
07:00AM	Loading…
Jul-15-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) -7.06%
Jun-21-25 08:00AM	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting (GlobeNewswire)
08:00AM	Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial (GlobeNewswire)
08:00AM	Perspective Therapeutics Commences Recruitment for [212Pb]VMT--NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial (GlobeNewswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
May-30-25 05:21PM	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting (GlobeNewswire) -7.00%
05:21PM	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT--NET at the 2025 ASCO Annual Meeting (GlobeNewswire)
May-21-25 11:22AM	Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential (Insider Monkey) -13.07%
May-12-25 04:43PM	Perspective Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +6.81%
04:36PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results (GlobeNewswire)
May-01-25 07:00AM	Perspective Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors (GlobeNewswire)
07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP- Positive Solid Tumors (GlobeNewswire)
Apr-23-25 12:25PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) +8.88%
12:25PM	Perspective Therapeutics Announces Acceptance of VMT- -NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire)
07:00AM	Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last? (Zacks)
Apr-17-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-11-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Apr-09-25 12:08AM	Is Now The Time To Invest In Perspective Therapeutics (Seeking Alpha) +11.11%
Apr-02-25 09:35AM	Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround (Zacks)
Mar-31-25 07:00AM	Perspective Therapeutics to Participate in Upcoming April Investor Conferences (GlobeNewswire)
Mar-26-25 04:10PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results (GlobeNewswire) -8.10%
Mar-17-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Feb-26-25 07:00AM	Perspective Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-21-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results (GlobeNewswire)
Feb-05-25 07:00AM	Perspective Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire) +5.67%
Jan-24-25 12:18PM	Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars (Benzinga) +10.47%
07:00AM	Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
07:00AM	Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-22-25 07:00AM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
07:00AM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
Jan-14-25 08:35AM	Perspective Therapeutics provides business updates, strategic priorities (TipRanks) -5.88%
Jan-13-25 08:00AM	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-10-25 07:00AM	Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 08:00AM	Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer (GlobeNewswire)
Nov-27-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in December (GlobeNewswire) -6.36%
Nov-26-24 07:00AM	Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital (TipRanks) +19.24%
06:45AM	Perspective Therapeutics downgraded to Neutral from Buy at BofA (TipRanks)
Nov-21-24 07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire) -51.38%
07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire)
Nov-16-24 01:26AM	Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-15-24 04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire) -11.66% -11.68%
04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire)
Nov-12-24 04:37PM	Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -6.94%
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results (GlobeNewswire)
Oct-31-24 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire)
Oct-23-24 07:00AM	Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) -5.65%
Oct-16-24 07:00AM	Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey (GlobeNewswire)
Oct-12-24 10:18AM	Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies (Insider Monkey)
Oct-11-24 08:30AM	Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research (GlobeNewswire)
Oct-10-24 05:14PM	Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research (GlobeNewswire)
Oct-07-24 07:00AM	Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day (GlobeNewswire)
Sep-30-24 07:00AM	Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) +6.21%
Sep-10-24 07:00AM	Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024 (GlobeNewswire)
Sep-05-24 07:00AM	Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma (GlobeNewswire)
Aug-28-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-13-24 09:40AM	Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year? (Zacks) +5.71%
Aug-12-24 04:35PM	Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results (GlobeNewswire)
Jul-30-24 07:00AM	Perspective Therapeutics to Participate at Upcoming Investor Conferences in August (GlobeNewswire)
Jul-25-24 06:15AM	3 Outperforming Stocks Surpassing Even Nvidia This Year (InvestorPlace) +6.24%
Jul-22-24 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet (Zacks)
Jun-12-24 07:00AM	Perspective Therapeutics Announces Inclusion in the Russell 3000 Index (GlobeNewswire) +5.56%
Jun-11-24 07:00AM	Perspective Therapeutics Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Jun-10-24 04:10PM	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire) +8.33%
May-24-24 08:01AM	Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-20-24 07:00AM	Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 (GlobeNewswire)

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hunt Jonathan Robert	Chief Accounting Officer	Nov 13 '25	Buy	2.03	11,000	22,295	59,800	Nov 17 08:01 AM
Williamson Robert F III	Director	Nov 12 '25	Buy	2.10	9,498	19,946	9,864	Nov 14 08:00 AM
Spoor Johan M.	Chief Executive Officer	Mar 28 '25	Buy	2.24	22,026	49,384	59,383	Apr 01 06:44 PM
Spoor Johan M.	Chief Executive Officer	Mar 28 '25	Buy	2.21	4,650	10,288	4,650	Apr 01 06:44 PM
Williamson Robert F III	Director	Mar 31 '25	Buy	2.14	38,145	81,775	108,982	Apr 01 05:04 PM
Williamson Robert F III	Director	Mar 28 '25	Buy	2.27	22,192	50,376	70,837	Apr 01 05:04 PM
Graham Juan	Chief Financial Officer	Mar 28 '25	Buy	2.25	33,333	74,946	35,354	Apr 01 05:03 PM
Woods Lori A	Director	Mar 31 '25	Buy	2.13	23,475	49,999	183,460	Apr 01 05:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CATX

Perspective Therapeutics Inc

Upgrade your FINVIZ experience